Brentuximab vedotin monotherapy (1.8 mg/kg IV q3 weeks × up to 16 cycles) for r/r systemic ALCL
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-BRENTUXIMAB-VEDOTIN |
|---|
| ID | REG-BV-MONO-SYSTEMIC-ALCL |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-PTCL-2024 SRC-NCCN-BCELL-2025 |
Notes
SGN-35-005 trial (Pro 2012, follow-up 2017): r/r systemic ALCL (n=58) — ORR 86%, CR 57%, mDOR 12.6 mo, 5-year OS ~60%. Best response rates of any single agent in r/r T-cell lymphoma. ALCL is universally CD30+ (~100% by IHC) — strongest BV target. Often used as bridge to autoSCT or alloSCT in transplant-eligible responders. Also used in primary cutaneous ALCL per ALCANZA-style schedule.
Used By
Indication
IND-ALCL-2L-BRENTUXIMAB-MONO- IND-ALCL-2L-BRENTUXIMAB-MONO